Pharmaceutical

AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal

The deal is worth approximately $1.2bn in combined upfront and potential contingent value payments and is expected to close in Q1 2024.

Dec 28, 2023 - 18:00
AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal
The deal is worth approximately $1.2bn in combined upfront and potential contingent value payments and is expected to close in Q1 2024.
Read the original article

Tags:

Previous Article

ARTBIO divulges plans for proprietary isotope manufacturing technology

Next Article

Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NPX-267 by NextPoint Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Transitional Cell...

Jun 14, 2024

Living in disadvantaged neighborhoods linked to higher dementia risk, study finds

Living in disadvantaged neighborhoods linked to higher ...

Jul 20, 2023

Boehringer reinforces interest in NASH with new $2bn deal  

Boehringer reinforces interest in NASH with new $2bn de...

Jan 3, 2024